Cadrenal Therapeutics announced the acquisition of eXIthera's assets, boosting its anticoagulation pipeline.
The deal includes novel Factor XIa inhibitors for acute and chronic anticoagulation settings.
This strategic move aims to address critical gaps in current antithrombotic treatments.
Acquisition Benefits
Adds novel assets in acute and chronic anticoagulation settings, enhancing the pipeline.
Unique Positioning
Cadrenal now develops both tecarfarin, a novel Vitamin K antagonist, and Factor XIa inhibitors.
Distinct Mechanism
eXIthera's inhibitors target Factor XIa specifically, offering high potency and selectivity.
Long-term Vision
Cadrenal aims to lead in anticoagulation, catering to patients with cardiovascular thrombotic risk.
- The acquisition expands Cadrenal's capabilities to address critical gaps in anticoagulation therapy.
- Factor XIa inhibitors offer a promising alternative to current anticoagulants with reduced bleeding risk.
- Cadrenal is strategically positioned to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk.
With the acquisition of eXIthera's assets, Cadrenal Therapeutics strengthens its position in the anticoagulation market and sets a path for innovative therapies.